Systematic Reviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Apr 22, 2024; 15(1): 91100
Published online Apr 22, 2024. doi: 10.4291/wjgp.v15.i1.91100
Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease
Suprabhat Giri, Prajna Anirvan, Sumaswi Angadi, Ankita Singh, Anurag Lavekar
Suprabhat Giri, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, Odisha, India
Prajna Anirvan, Department of Gastroenterology, Kalinga Gastroenterology Foundation, Cuttack, 753001, Odisha, India
Sumaswi Angadi, Department of Gastroenterology, Nizam’s Institute of Medical Sciences, Hyderabad 500082, Telangana, India
Ankita Singh, Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Mumbai 400012, Maharashtra, India
Anurag Lavekar, Department of Gastroenterology, Sagar Hospital, Bengaluru 560041, Karnataka, India
Author contributions: Giri S and Lavekar A contributed to the conception and design of the manuscript; Giri S, Angadi S, and Singh A contributed to the literature review, analysis, data collection, and interpretation; Giri S, Anirvan P, and Angadi S drafted the initial manuscript; Giri S and Lavekar A contributed to the critical revision of the initial manuscript; and all the authors approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2021 Checklist, and the manuscript was prepared and revised according to the PRISMA 2021 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anurag Lavekar, MD, Consultant Gastroenterologist, Department of Gastroenterology, Sagar Hospital, No. 44/54, 30th Cross Road, Extension, 4th T Block East, Tilak Nagar, Jayanagar, Bengaluru 560041, Karnataka, India. anuraglavekar@gmail.com
Received: December 21, 2023
Revised: February 9, 2024
Accepted: April 1, 2024
Published online: April 22, 2024
Core Tip

Core Tip: The prevalence of sarcopenia in nonalcoholic fatty liver disease (NAFLD) varies widely. Sarcopenia in NAFLD is consistently associated with a higher risk of advanced fibrosis. In addition to liver-related events, sarcopenia in NAFLD is associated with adverse outcomes, including an increased risk of nonalcoholic steatohepatitis, mortality, cardiovascular risks, and metabolic complications. The heterogeneity in prevalence and associations highlights the importance of accurately defining measurement modalities and cutoff criteria. Establishing consensus guidelines is crucial for advancing research and enhancing clinical management in the complex relationship between sarcopenia and NAFLD.